The stock of Novartis AG ADR (NVS) has seen a 2.45% increase in the past week, with a 12.96% gain in the past month, and a 10.59% flourish in the past quarter. The volatility ratio for the week is 0.38%, and the volatility levels for the past 30 days are at 1.16% for NVS. The simple moving average for the past 20 days is 5.24% for NVS’s stock, with a 10.57% simple moving average for the past 200 days.
Is It Worth Investing in Novartis AG ADR (NYSE: NVS) Right Now?
Novartis AG ADR (NYSE: NVS) has a price-to-earnings ratio that is above its average at 18.89x. The stock has a 36-month beta value of 0.59. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 9 as “hold,” and 2 as “sell.”
The public float for NVS is 1.90B, and at present, short sellers hold a 0.18% of that float. On June 12, 2025, the average trading volume of NVS was 2.13M shares.
NVS) stock’s latest price update
The stock of Novartis AG ADR (NYSE: NVS) has increased by 2.20 when compared to last closing price of 118.07.Despite this, the company has seen a gain of 2.45% in its stock price over the last five trading days. globenewswire.com reported 2025-06-12 that Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the Hb level improved on average by 2.01 g/dL (95% CI, 1.74, 2.29) with most patients achieving normal or near-normal levels 1. Data will be presented at the European Hematology Association (EHA) Congress 2025.
NVS Trading at 8.18% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.21% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Marshall Fiona, who proposed sale 15,000 shares at the price of $112.68 back on May 23 ’25. After this action, Marshall Fiona now owns shares of Novartis AG ADR, valued at $1,690,181 using the latest closing price.
Kowalski Robert William, the Officer of Novartis AG ADR, proposed sale 1,212 shares at $113.28 during a trade that took place back on Apr 30 ’25, which means that Kowalski Robert William is holding shares at $137,297 based on the most recent closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.76 for the gross margin
The net margin for Novartis AG ADR stands at 0.24. The total capital return value is set at 0.23. Equity return is now at value 32.95, with 13.24 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.61. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is 20.17.
Currently, EBITDA for the company is 20.71 billion with net debt to EBITDA at 1.11. When we switch over and look at the enterprise to sales, we see a ratio of 4.76. The receivables turnover for the company is 6.1for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.79.
Conclusion
To sum up, Novartis AG ADR (NVS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
